USE OF INHALATION ANESTHETICS DURING CARDIOPULMONARY BYPASS
https://doi.org/10.21292/2078-5658-2018-15-4-70-75
Abstract
Protection of myocardium from ischemic and reperfusion lesions continues to be an important issue in the modern cardiac surgery. Russian and foreign publications contain a significant number of data about the protective impact of pre- and post-conditioning with inhalation anesthetics (sevoflurane, isoflurane, and desflurane) on the myocardium. The article highlights that this protective action is maximum when these drugs are used during the whole operation and it means during cardiopulmonary bypass as well. Therefore, currently, the listed above inhalation anesthetics are used fairly frequent during cardiopulmonary bypass. However, the technology of inhalation anesthesia during perfusion has a number of specific features: changes in the pharmacokinetics of drugs (which provides impact on the dosing of anesthetics), design of oxygenator, which plays a certain role when the anesthetics are supplied to the blood, monitoring during inhalation anesthesia, technical assistance for this technology and important safety issues. This review describes the above-mentioned aspects.
About the Authors
E. Yu. Chepurnyak
B.V. Petrovsky Russian Research Surgery Center.
Russian Federation
Russian Federation
Evgenya Yu. Chepurnyak Resident, Anesthesiology and Intensive Care Department.
2, Abrikosovsky Lane, Moscow, 119991.
A. V. Panov
B.V. Petrovsky Russian Research Surgery Center.
Russian Federation
Russian Federation
Aleksandr V. Panov Anesthesiologist and Emergency Physician of Department of Anesthesiology and Intensive Care with Cardiopulmonary Bypass.
2, Abrikosovsky Lane, Moscow, 119991.
L. S. Lokshin
B.V. Petrovsky Russian Research Surgery Center.
Russian Federation
Russian Federation
Leonid S. Lokshin Doctor of Medical Sciences, Professor, Head of Department of Anesthesiology and Intensive Care with Cardiopulmonary Bypass.
2, Abrikosovsky Lane, Moscow, 119991.
References
1. Gerasimenko O.N., Grebenchikov O.А., Ovezov А.M. et al. Anesthetic pre-conditioning in cardiac surgery. Аlmanakh Klinicheskoy Meditsiny, 2017, vol. 45, no. 3, pp. 172-180. (In Russ.)
2. Grishin А.V., Yavorovskiy А.G., Charchyan E.R. et al. Pharmacological post-conditioning of myocardium with sevoflurane in the patients undergoing cardiac surgery. Аnesteziolog. i Reanimatolog., 2016, vol. 61, no. 5, pp. 348-352. (In Russ.)
3. Calvey T.N., Williams N.E. Ingalyatsionnye anestetiki. V kn: Farmakologiya dlya anesteziologa (Russ. Ed.: Inhalation anesthetics. in: Calvey T.N., Williams N.E. Principles and Practices of Pharmacology for Anaesthetists). Moscow, Izdatelstvo BINOM Publ., 2007, pp. 91-115.
4. Molchan N.S., Polushin Yu.S., Zhloba А.А. et al. Impact of anesthesia with prolonged use of desflurane and sevoflurane on the cardiac function in coronary artery bypass graft surgeries with cardiopulmonary bypass. Vestn. Anesteziologii I Reanimatologii, 2017, vol. 14, no. 4, pp. 23-31. (In Russ.)
5. Barry A.E., Chaney M.A., London M.J. Anesthetic management during cardiopulmonary bypass: a systematic review. Anesth. Analg., 2015, vol. 120, no. 4, pp. 749-769.
6. Bignami E., Guarnieri M., Pieri M. et al. Volatile anaesthetics added to cardiopulmonary bypass are associated with reduced cardiac troponin. Perfusion, 2017, vol. 32, no. 7, pp. 547-553.
7. Blokker-Veldhuis M.J., Rutten P.M., de Hert S.G. Occupational exposure to sevoflurane during cardiopulmonary bypass. Perfusion, 2011, vol. 26, no. 5, pp. 383-389.
8. de Hert S.G., Van der Linden P.J., Cromheecke S. et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology, 2004, vol. 101, no. 2, pp. 299-310.
9. de Hert S., Vlasselaers D., Barbé R. et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia, 2009, vol. 64, no. 9, pp. 953-960.
10. Fellahi J.-L., Gue X., Philippe E. et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. Eur. J. Anaesthesiol., 2004, vol. 21, no. 9, pp. 688-693
11. Frässdorf J., de Hert S., Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br. J. Anaesth., 2009, vol. 103, no. 1, pp. 89-98.
12. Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff, 2000. Available at: https://www.fda.gov/RegulatoryInformation/Guidances/ucm073668.htm
13. Henderson J.M., Nathan H.J., Lalande M. et al. Washin and washout of isoflurane during cardiopulmonary bypass. Can J Anaesth., 1988, vol. 35, no. 6, pp. 587-590.
14. Jack T. Inhalation anaesthetics and the Medtronic Maxima Plus membrane oxygenator. Br. J. Anaesth., 1998, vol. 80, no. 6, pp. 878.
15. Landoni G., Bignami E., Oliviero F. et al. Halogenated anaesthetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann. Card Anaesth., 2009, vol. 12, no. 1, pp. 4-9.
16. Lim H.S., Cho S.H., Kim D.K. et al. Isoflurane cracks the polycarbonate connector of extra-corporeal circuit − a case report. Korean. J. Anesthesiol., 2010, vol. 58, no. 3, pp. 304-306.
17. Lockwood G.G., Sapsed-Byrne S.M., Adams S.A comparison of anaesthetic tensions in arterial blood and oxygenator exhaust gas during cardiopulmonary bypass. Anaesthesia, 1999, vol. 54, no. 5, pp. 434-436.
18. Maltry D.E., Eggers G.W.Jr. Isoflurane-induced failure of the Bentley-10 oxygenator. Anesthesiology, 1987, vol. 66, no. 1, pp. 100-101.
19. McMullan V., Alston R.P., Tyrrell J. Volatile anaesthesia during cardiopulmonary bypass. Perfusion, 2015, vol. 30, no. 1, pp. 6-16.
20. Medtronic. Medtronic manual. User manual: Medtronic affinity fusion oxygenator, 2012. Available at: https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=16&ved=0ahUKEwitiauxl-faAhUJ2ywKHZ2hCGMQFghzMA8&url=https%3A%2F%2Fkategorizacia.mzsr.sk%2FPomocky%2FDownload%2FRequestAttachment%2F32925&usg=AOvVaw2pBGUnMChm5X7Id5w1EvI9
21. Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol. Scand., 2000, vol. 44, no. 3, pp. 261-273.
22. Mierdl S., Byhahn C., Abdel-Rahman U. et al. Occupational exposure to inhalational anesthetics during cardiac surgery on cardiopulmonary bypass. Ann. Thorac. Surg., 2003, vol. 75, no. 6, pp. 1924-1927.
23. Montoya J.P., Shanley C. J., Merz S.I. et al. Plasma leakage through microporous membranes. Role of phospholipids. ASAIO J., 1992, vol. 38, no. 3, pp. 399-405.
24. Mottaghy K., Oedekoven B., Starmans H. et al. Technical aspects of plasma leakage prevention in microporous capillary membrane oxygenators. ASAIO Trans., 1989, vol. 35, no. 3, pp. 640-643.
25. Nigro Neto C., Landoni G., Cassarà L. et al. Use of volatile anesthetics during cardiopulmonary bypass: a systematic review of adverse events. J. Cardiothorac. Vasc. Anesth., 2014, vol. 28, no. 1, pp. 84-89.
26. Nitzschke R., Wilgusch J., Kersten J.F. et al. Changes in sevoflurane plasma concentration with delivery through the oxygenator during on-pump cardiac surgery. Br. J. Anaesth., 2013, vol. 110, no. 6, pp. 957-965.
27. Nordén I. The influence of anaesthetics on systemic vascular resistance during cardiopulmonary bypass. Scand. J. Thorac. Cardiovasc. Surg., 1974, vol. 8, pp. 81-87.
28. Nussmeier N.A., Cohen N.H., Moskowitz G.J. et al. Washin and washout of three volatile anesthetics concurrently administered during cardiopulmonary bypass. Anesthesiology, 1988, vol. 69, pp. A84.
29. Nussmeier N.A., Lambert M.L., Moskowitz G.J. et al. Washin and washout of isoflurane administered via bubble oxygenators during hypothermic cardiopulmonary bypass. Anesthesiology, 1989, vol. 71, no. 4, pp. 519-525.
30. Nussmeier N.A., Moskowitz G.J., Weiskopf R.B. et al. 2nd. In vitro anesthetic washin and washout via bubble oxygenators: influence of anesthetic solubility and rates of carrier gas inflow and pump blood flow. Anesth. Analg., 1988, vol. 67, no. 10, pp. 982-987.
31. Stern R.C., Weiss C.I., Steinbach J.H. et al. Isoflurane uptake and elimination are delayed by absorption of anesthetic by the Scimed membrane oxygenator. Anesth. Analg., 1989, vol. 69, no. 5, pp. 657-662.
32. Symons J.A., Myles P.S. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br. J. Anaesth., 2006, vol. 97, no. 2, pp. 127-136.
33. Wiesenack C., Wiesner G., Keyl C. et al. In vivo uptake and elimination of isoflurane by different membrane oxygenators during cardiopulmonary bypass. Anesthesiology, 2002, vol. 97, no. 1, pp. 133-138.
34. Zhou J.X., Liu J. Dynamic changes in blood solubility of desflurane, isoflurane, and halothane during cardiac surgery. J. Cardiothorac. Vasc. Anesth., 2001, vol. 15, no. 5, pp. 555-559.
Review
For citations:
Chepurnyak E.Yu., Panov A.V., Lokshin L.S. USE OF INHALATION ANESTHETICS DURING CARDIOPULMONARY BYPASS. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(4):70-75. (In Russ.) https://doi.org/10.21292/2078-5658-2018-15-4-70-75
Email this article 